Rohto Pharmaceutical Co.,Ltd.
Stock Price Chart
2026/08/21 UpdatedPrice Trend
2026/08/21 UpdatedPrice & Trading Details
2026/08/21 UpdatedPRICE
TRADING
Analyst Recommendations 11 analysts
Updated 2026/08/01Earnings Calendar
Updated 2026/08/01Recent Earnings
| Date | EPS Est. | EPS Actual | Surprise |
|---|---|---|---|
| 2026/05/12 | ¥30.36 | ¥26.41 | -13.0% |
| 2026/02/11 | ¥44.11 | ¥47.03 | +6.6% |
| 2025/11/12 | ¥24.91 | ¥26.03 | +4.5% |
| 2025/05/12 | ¥24.96 | ¥27.38 | +9.7% |
Shareholder Composition
Updated 2026/08/01Major Holders
Updated 2026/08/01| Institution | Ownership | Shares | Change |
|---|---|---|---|
|
MFS SERIES TRUST X-MFS International Intrinsic Value Fund
|
10.2M | 0.00% | |
|
VANGUARD STAR FUNDS-Vanguard Total International Stock Index Fund
|
2.9M | +0.06% | |
|
VANGUARD TAX-MANAGED FUNDS-Vanguard Developed Markets Index Fund
|
2.0M | +3.29% | |
|
iShares Trust-iShares Core MSCI EAFE ETF
|
1.4M | 0.00% | |
|
Goldman Sachs TRT-Goldman Sachs Intl Small Cap Insights Fd.
|
982.9K | +1.98% | |
|
iShares Trust-iShares MSCI EAFE Small-Cap ETF
|
737.3K | -0.24% |
Dividend History
Updated 2026/08/23| Year | Dividend | Change |
|---|---|---|
| 2026 | ¥25 | -39.0% |
| 2025 | ¥41 | +32.3% |
| 2024 | ¥31 | +29.2% |
| 2023 | ¥24 | +17.1% |
| 2022 | ¥21 | - |
Financial Performance
2026/08/23 UpdatedRevenue & Profit
Margins
Cash Flow
Financial Health
| 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|
| Income Statement | ||||
| Revenue | ¥199,646M | ¥238,664M | ¥270,840M | ¥308,625M |
| Gross Profit | ¥116,170M | ¥137,421M | ¥157,285M | ¥174,939M |
| Operating Income | ¥29,019M | ¥33,964M | ¥40,052M | ¥38,943M |
| Pretax Income | ¥28,122M | ¥34,537M | ¥41,714M | ¥43,280M |
| Net Income | ¥21,127M | ¥26,377M | ¥30,936M | ¥31,006M |
| EPS | ¥92.34 | ¥115.29 | ¥135.21 | ¥135.44 |
| Operating Margin | 14.54% | 14.23% | 14.79% | 12.62% |
| Balance Sheet | ||||
| Total Assets | ¥274,876M | ¥309,677M | ¥346,175M | ¥421,875M |
| Total Equity | ¥178,398M | ¥209,568M | ¥246,323M | ¥260,093M |
| Total Liabilities | ¥96,478M | ¥100,109M | ¥99,852M | ¥161,782M |
| Cash | ¥72,791M | ¥79,951M | ¥89,210M | ¥77,161M |
| Interest-bearing Debt | ¥21,383M | ¥11,693M | ¥10,494M | ¥50,223M |
| Equity Ratio | 64.90% | 67.67% | 71.16% | 61.65% |
| D/E Ratio | 0.12 | 0.06 | 0.04 | 0.19 |
| Cash Flow | ||||
| Operating CF | ¥27,250M | ¥30,924M | ¥34,245M | ¥36,917M |
| Investing CF | -¥16,406M | -¥13,176M | -¥16,317M | -¥89,170M |
| Financing CF | ¥3,470M | -¥16,199M | -¥13,784M | ¥35,319M |
| Free CF | ¥15,922M | ¥21,016M | ¥25,333M | ¥26,356M |
| Efficiency | ||||
| ROE | 11.84% | 12.59% | 12.56% | 11.92% |
| ROA | 7.69% | 8.52% | 8.94% | 7.35% |
Latest IR Information
-
Rohto Pharmaceutical Co., Ltd. Q1 2027 Consolidated Financial Highlights
Announced Q1 2027 consolidated results and earnings guidance. Net sales of 91,624 million yen, operating income of 13,663 million yen, a marked YoY profit increase. Mentions contributions by segments and outlook revisions.
Read more -
Notice Regarding the Revision of Earnings Forecast
Consolidated earnings forecast for the fiscal year ending March 2027 raised. Net sales increased by 2,800 million yen from the previous forecast, operating income by 2,700 million yen, ordinary income by 1,300 million yen, net income attributable to owners of...
Read more -
Rohto Pharmaceutical Co., Ltd. 2027 Fiscal Year Q1 Consolidated Financial Results (Interim) (Consolidated)
Discloses trends in net sales and profits. For the consolidated results for the first quarter of the 2027 fiscal year, presents figures for net sales, operating income, and net income, by segment and for the company as a whole, with...
Read more -
[Rohto Pharmaceutical] Completion of Subsidiary Acquisition of Thann Oryza | May 2026
Rohto Pharmaceutical completed the share acquisition of Thann Oryza and became its parent company on May 29, 2026. The impact on future earnings is under review, and additional information will be disclosed when available.
Read more -
【Rohto Pharmaceutical】Conversion Price Adjustment for April 2026 | May 21, 2026
Rohto Pharmaceutical approved the year-end dividend plan at the Board of Directors meeting held on May 21, 2026, and implemented a conversion price adjustment applicable from April 1, 2026.
Read more
Latest News (5 items)
-
Average Analyst Rating: none
Average Target Price: ¥2,939
Rating Score: 1.91 (Based on 11 analysts)
※1=Strong Buy, 5=Strong Sell
Company Information
About
Rohto Pharmaceutical Co.,Ltd. manufactures and markets pharmaceutical products, cosmetics, and functional foods Japan, China, and internationally. The company provides eye care products, such as eye drops, care for contact lenses, and eye wash; and facial care products comprising face wash, lotions, and creams. It also offers medicine and medicated products for skin, lip balms, sunscreens, functional cosmetics, etc.; medicine for internal use, such as digestive and herbal medicines; regenerative medicines; OTC pharmaceutical products, including ophthalmic, dermatological, gastrointestinal, and diagnostic drugs, as well as Chinese herbal medicines, and supplements. In addition, the company operates beauty counters that provide beauty and health services; and manufactures and sells diagnostic reagents, as well as provides investment management services; and contract development and manufacturing services. The company was formerly known as Yamada Pharmaceutical and changed its name to Rohto Pharmaceutical Co.,Ltd. in September 1949. The company was founded in 1899 and is headquartered in Osaka, Japan.
